Dataset Information

In-gap quasiparticle excitations induced by non-magnetic Cu impurities in Na(Fe(0.96) Co(0.03)Cu(0.01))As revealed by scanning tunnelling spectroscopy.

ABSTRACT: The origin of superconductivity in the iron pnictides remains unclear. One suggestion is that superconductivity in these materials has a magnetic origin, which would imply a sign-reversal s(±) pairing symmetry. Another suggests it is the result of orbital fluctuations, which would imply a sign-equal s(++) pairing symmetry. There is no consensus yet which of these two distinct and contrasting pairing symmetries is the right one in iron pnictide superconductors. Here we explore the nature of the pairing symmetry in the superconducting state of Na(Fe0.97-xCo0.03Cux)As by probing the effect of scattering of Cooper pairs by non-magnetic Cu impurities. Using scanning tunnelling spectroscopy, we identify the in-gap quasiparticle states induced by the Cu impurities, showing signatures of Cooper pair breaking by these non-magnetic impurities-a process that is only consistent with s(±) pairing. This experiment provides strong evidence for the s(±) pairing.

SUBMITTER: Yang H

PROVIDER: S-EPMC3868228 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

In-gap quasiparticle excitations induced by non-magnetic Cu impurities in Na(Fe(0.96) Co(0.03)Cu(0.01))As revealed by scanning tunnelling spectroscopy.

Yang Huan H Wang Zhenyu Z Fang Delong D Deng Qiang Q Wang Qiang-Hua QH Xiang Yuan-Yuan YY Yang Yang Y Wen Hai-Hu HH

Nature communications 20130101

The origin of superconductivity in the iron pnictides remains unclear. One suggestion is that superconductivity in these materials has a magnetic origin, which would imply a sign-reversal s(±) pairing symmetry. Another suggests it is the result of orbital fluctuations, which would imply a sign-equal s(++) pairing symmetry. There is no consensus yet which of these two distinct and contrasting pairing symmetries is the right one in iron pnictide superconductors. Here we explore the nature of the p ...[more]

PMID: 24248097

Similar Datasets

Project description:BackgroundThe purpose of this study was to evaluate the intraocular pressure (IOP)-lowering efficacy and safety of bimatoprost 0.01% or 0.03% as monotherapy in patients treated with latanoprost 0.005% monotherapy who require additional IOP lowering for their ocular hypertension or open-angle glaucoma.MethodsTwo prospective, investigator-masked, randomized, parallel-group, multicenter studies enrolled patients with baseline IOP ≥20 mmHg after ≥30 days of latanoprost 0.005% monotherapy. Patients were randomized to 12 weeks of study treatment (study 1, bimatoprost 0.01% once daily or bimatoprost 0.01% once daily plus brimonidine 0.1% three times daily; study 2, bimatoprost 0.03% once daily or bimatoprost 0.03% once daily plus fixed-combination brimonidine 0.2%/timolol 0.5% twice daily). Patient evaluations at weeks 4 and 12 included IOP at 8 am, 10 am, and 4 pm and safety assessments. Results in the monotherapy study arms (bimatoprost 0.01% or 0.03%) are presented.ResultsLatanoprost-treated baseline mean diurnal IOP (± standard error of the mean) was 22.2±0.3 mmHg and 22.1±0.4 mmHg in the bimatoprost 0.01% and bimatoprost 0.03% treatment arms, respectively (P=0.957). In both treatment arms, mean (± standard error of the mean) reduction in IOP from latanoprost-treated baseline was statistically significant at each time point at both follow-up visits (P<0.001), ranging from 3.7±0.4 (17.0%) mmHg to 4.4±0.4 (19.9%) mmHg with bimatoprost 0.01% and from 2.8±0.5 (12.8%) mmHg to 3.9±0.5 (16.7%) mmHg with bimatoprost 0.03%. Mean percentage IOP reduction from latanoprost-treated baseline was numerically greater with bimatoprost 0.01% than with bimatoprost 0.03% throughout follow-up. The incidence of conjunctival hyperemia of mild or greater severity increased from latanoprost baseline after 12 weeks of treatment only in the bimatoprost 0.03% treatment arm.ConclusionMany patients who do not reach their target IOP on latanoprost can achieve additional IOP lowering and maintain monotherapy by replacing latanoprost with bimatoprost. Reductions in IOP from latanoprost baseline were larger with bimatoprost 0.01% than with bimatoprost 0.03%, and bimatoprost 0.01% had a more favorable tolerability profile.

Dataset Information

In-gap quasiparticle excitations induced by non-magnetic Cu impurities in Na(Fe(0.96) Co(0.03)Cu(0.01))As revealed by scanning tunnelling spectroscopy.

Publications

In-gap quasiparticle excitations induced by non-magnetic Cu impurities in Na(Fe(0.96) Co(0.03)Cu(0.01))As revealed by scanning tunnelling spectroscopy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets